ANTENGENE ANNOUNCES FIRST PATIENT DOSED IN PHASE I ATTRACT STUDY EVALUATING ATG-201 (CD19 × CD3 TCE) FOR B CELL-MEDIATED AUTOIMMUNE DISEASES

Reuters · 3d ago

Please log in to view news